RxDoctor Payments Data

Cory Lord

Nurse Practitioner · Lakeland, FLNPI 1619007002

Payments from drug & device makers

$316in general payments, 2019–2025

Across 5 payments — averaging $63.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$125
  • Esperion Therapeutics, Inc.$99
  • Medtronic$69
  • AbbVie$22

What the payments were for

  • Food & beverage$316100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk1$125
Esperion Therapeutics, Inc.1$99
Medtronic2$69
AbbVie1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$316 in reported general payments places this provider in the 55th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$300,468
Medicare patients
333
Services billed
2,809

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban517$269,065
TrulicityDulaglutide182$187,336
MyrbetriqMirabegron190$92,299
XareltoRivaroxaban113$65,101
NuplazidPimavanserin Tartrate13$62,649
OzempicSemaglutide56$61,947
JanuviaSitagliptin Phosphate55$25,813
Breo ElliptaFluticasone/Vilanterol52$22,439
JardianceEmpagliflozin36$20,912
Potassium Chloride875$18,213
RexultiBrexpiprazole15$17,351
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog47$15,824
FarxigaDapagliflozin Propanediol22$12,066
Pantoprazole Sodium532$11,915
Duloxetine Hcl322$11,783

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$125$61,94756 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Lakeland

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →